Chronic Lymphocytic Leukemia

Beyond Complexity: Why Molecular Features Still Dictate the Prognosis of Chronic Lymphocytic Leukemia

By MedXY 03/13/2026

Emerging data from UK clinical trials indicate that while high genomic complexity (HGC) correlates with poor outcomes in CLL, it often serves as a surrogate for other established high-risk markers like TP53 status and telomere length.

news Oncology

Adding Ianalumab to Ibrutinib Induces Deep Remissions and Enables Therapy Discontinuation in Chronic Lymphocytic Leukemia

By MedXY 01/13/2026

A Phase Ib study reveals that adding the anti-BAFF-R antibody ianalumab to ibrutinib therapy achieves high rates of undetectable measurable residual disease (uMRD), allowing over 40% of CLL patients to successfully discontinue long-term treatment while maintaining remission.

Clinical Updates Hematology-Oncology news

Advancing Chronic Lymphocytic Leukemia Management: The Impact of Measurable Residual Disease-Guided Ibrutinib-Venetoclax Therapy

By MedXY 09/26/2025

Phase 3 trial data demonstrate that ibrutinib-venetoclax therapy achieves superior undetectable measurable residual disease rates and significantly prolonged progression-free survival compared with ibrutinib alone or FCR in chronic lymphocytic leukemia.